Technical Analysis for BLCM - Bellicum Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 7.58 -0.52% -0.04
BLCM closed down 0.52 percent on Thursday, July 19, 2018, on 37 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical BLCM trend table...

Date Alert Name Type % Chg
Jul 19 Bollinger Band Squeeze Range Contraction 0.00%
Jul 19 Narrow Range Bar Range Contraction 0.00%
Jul 19 NR7 Range Contraction 0.00%
Jul 19 Inside Day Range Contraction 0.00%
Jul 19 Down 3 Days in a Row Weakness 0.00%
Jul 19 Down 4 Days in a Row Weakness 0.00%
Jul 18 Bollinger Band Squeeze Range Contraction -0.52%
Jul 18 Down 3 Days in a Row Weakness -0.52%
Jul 17 Bollinger Band Squeeze Range Contraction -4.41%
Jul 17 Inside Day Range Contraction -4.41%

Older signals for BLCM ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of various forms of cancer. Its lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation. The company is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Its preclinical product candidates include BPX-401, a chimeric antigen receptor (CAR-T) product candidate for the treatment of hematological cancers that express the CD19 antigen; BPX-601, a CAR-T product candidate for treating solid tumors overexpressing the prostate stem cell antigen; and BPX-701, a TCR product candidate for the treatment of solid tumors expressing the preferentially-expressed antigen in melanoma. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.
Is BLCM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 13.3
52 Week Low 5.02
Average Volume 683,457
200-Day Moving Average 8.3486
50-Day Moving Average 8.2014
20-Day Moving Average 7.921
10-Day Moving Average 8.043
Average True Range 0.3949
ADX 14.47
+DI 17.8099
-DI 25.4273
Chandelier Exit (Long, 3 ATRs ) 7.9153
Chandelier Exit (Short, 3 ATRs ) 8.4747
Upper Bollinger Band 8.4532
Lower Bollinger Band 7.3888
Percent B (%b) 0.18
BandWidth 13.437697
MACD Line -0.1147
MACD Signal Line -0.0651
MACD Histogram -0.0496
Fundamentals Value
Market Cap 251.85 Million
Num Shares 33.2 Million
EPS -2.94
Price-to-Earnings (P/E) Ratio -2.58
Price-to-Sales 975.18
Price-to-Book 2.56
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.87
Resistance 3 (R3) 7.86 7.77 7.82
Resistance 2 (R2) 7.77 7.69 7.77 7.80
Resistance 1 (R1) 7.67 7.65 7.63 7.68 7.79
Pivot Point 7.58 7.58 7.55 7.58 7.58
Support 1 (S1) 7.48 7.50 7.44 7.49 7.37
Support 2 (S2) 7.39 7.46 7.39 7.36
Support 3 (S3) 7.29 7.39 7.34
Support 4 (S4) 7.30